Effect of fluticasone propionate/salmeterol plus tiotropium versus tiotropium on walking endurance in COPD

European Respiratory Journal

Volumn 42, Issue 2, 2013, Pages 539-541

  Maltais, Franćois ^a   Mahler, Donald A ^b   Pepin, Véronique ^c   Nadreau, Eric ^a   Crater, Glenn D ^d   Morris, Andrea N ^e   Emmett, Amanda H ^e   Ferro, Thomas J ^e  

^a LAVAL UNIVERSITY   (Canada)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^d GLAXOSMITHKLINE   (Canada)

^e GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE PROPIONATE PLUS SALMETEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; PLACEBO; SALBUTAMOL; TIOTROPIUM BROMIDE;

ADULT; CANADA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENDURANCE; EXERCISE TOLERANCE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNITED STATES; UNSPECIFIED SIDE EFFECT; WALKING;

AGED; ALBUTEROL; ANDROSTADIENES; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; EXERCISE TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PHYSICAL ENDURANCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES; SYMPATHOMIMETICS; TREATMENT OUTCOME; WALKING;

EID: 84882579561     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00074113     Document Type: Letter

References (12)

1. Oga T, Nishimura K, Tsukino M, et al. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 2003; 167: 544-549.
2. O?Donnell DE, Flu?ge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832-840.
3. Maltais F, Hamilton A, Marciniuck D, et al. Improvements in symptom-limited exercise performance overh with once-daily tiotropium in patients with COPD. Chest 2005; 128: 1168-1178.
4. Bédard ME, Brouillard C, Pepin V, et al. Tiotropium improves walking endurance in COPD. Eur Respir J 2012; 39: 265-271.
5. Neder JA, Fuld JP, Overend T, et al. Effects of formoterol on exercise tolerance in severely disabled patients with COPD. Respir Med 2007; 101: 2056-2064.
6. Pepin V, Laviolette L, Brouillard C, et al. Significance of changes in endurance shuttle walking performance. Thorax 2011; 66: 115-120.
7. Pepin V, Saey D, Whittom F, et al. Walking versus cycling: sensitivity to bronchodilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 1517-1522.
8. Brouillard C, Pepin V, Milot J, et al. Endurance shuttle walk test: responsiveness to salmeterol in COPD. Eur Respir J 2008; 31: 579-584.
9. Pepin V, Brodeur J, Lacasse Y, et al. Six-minute walking versus shuttle walking: responsiveness to bronchodilation in chronic obstructive pulmonary disease. Thorax 2007; 62: 291-298.
10. Maltais F, Celli B, Casaburi R, et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir Med 2011; 105: 580-587.
11. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
12. O?Donnell DE, Sciurba F, Celli B, et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 2006; 130: 647-656.